SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) today reported financial results for the first quarter ended March 31, 2006. The Company reported total revenue of $82.3 million for the first quarter, including net product sales of $75.9 million. Net loss for the quarter ended March 31, 2006 was $67.9 million, or $0.61 per share. Pro forma net loss for the quarter ended March 31, 2006 was $57.0 million or $0.51 per share. This excludes stock-based compensation expense of $10.9 million, or $0.10 per share. At March 31, 2006, the Company held cash, cash equivalents and short-term investments of approximately $386 million. On April 5, 2006, the Company completed a public offering of 11.5 million shares of its common stock, generating net proceeds of approximately $508 million.
